Anthony Quinn

Anthony Quinn is Founder at IDBioPharm Consulting LLC.

Content by Anthony Quinn:

 Tools & Techniques Drug delivery

A Rare Delight

| Anthony Quinn

Anthony Quinn shares the story behind the development and approval of sebelipase alfa (Kanuma) – the first and only enzyme replacement therapy for lysosomal acid lipase deficiency (LAL-D).

About the author

| Charlotte Barker, William Aryitey, Michael Schubert, James Strachan, Karim Dabbagh, Ann Hayes, Thomas Conrads, Anthony Quinn, Niclas Nilsson, Eric Topol, Benoit Arveiler, Didier Raoult, Ewan McNay, Tamara Minko, Jennifer Van Eyk, Cathy Merry, Diane Hoffman-Kim, Robert Coffin, Helen Lambert , Julian Solway, Richard Holland, Jan Johannessen, Ameeta Parekh, Bradley Hyman, Michela Gallagher

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register

October Issue of The Translational Scientist